Answers are grounded in this paper and cite their sources.
We investigated the bioavailability of a synthetic form of the vitamin K2 molecule menaquinone-7 (MK-7) in a randomised single-blinded two-way cross-over study. Healthy subjects (20 – 66 years of age) took a single 180 μg dose of synthetic MK-7 or fermentation-derived MK-7, and serum MK-7 concentrations were monitored for 72 hours to calculate AUC(0 – 72 h) and Cmax. We also compared the biological effects of placebo, fermentation-derived MK-7 (90 μg) and 3 doses of synthetic MK-7(45, 90 and 180 μg) in a randomised double-blinded parallel study. Healthy subjects (20 – 60 years of age) took one of the supplements daily for 43 days, and the fraction of carboxylated osteocalcin (OC) was compared between day 1 and day 43 as a marker for vitamin K activity. In the bioavailability study, the 90 % confidence interval for the ratio of the AUC(0-72 h) values for synthetic and fermentationderived MK-7 was 83 – 111, indicating bioequivalence. The 90 % confidence interval for the Cmax ratio was 83 – 131. The serum concentrations of carboxylated OC and undercarboxylated OC were increased (p = 0.01) and reduced (p = 0.02), respectively, after daily intake of 180 μg of synthetic MK-7 for 43 days, indicating increased vitamin K activity. Across both studies, only 1 participant reported an adverse event (dry mouth; 180 μg synthetic MK-7 group, functional study) that was considered possibly related to synthetic MK-7 supplementation. Our findings provide evidence that the tested synthetic form of MK-7 is bioequivalent to fermentation-derived MK-7, exhibits vitamin K activity and is well tolerated in healthy subjects.
No takes yet. Share an insight, caveat, or question.
Møller et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: